Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: Still a matter of debate?

Interactive Cardiovascular and Thoracic Surgery

Volumn 15, Issue 1, 2012, Pages 109-114

  Mydina, Muhammad I ^a   Dimitrakakisb, Georgios ^b   Younisa, Jenan ^a   Nowella, Justin ^a   Athanasiouc, Thanos ^c   Kourliourosa, Antonios ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Aortic valve replacement; Aspirin; Bioprosthetic; Thromboprophylaxis; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DABIGATRAN; PHENINDIONE; RIVAROXABAN; TRIFLUSAL; WARFARIN;

AORTA VALVE REPLACEMENT; ARTICLE; BLEEDING; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG FATALITY; DRUG MEGADOSE; DRUG UTILIZATION; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART VALVE BIOPROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; OBSERVATIONAL STUDY; PATIENT MONITORING; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; STROKE; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION;

ANTICOAGULANTS; AORTIC VALVE; ASPIRIN; BIOPROSTHESIS; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME; WARFARIN;

EID: 84863458656     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivs102     Document Type: Article

References (25)

1. Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol 2010;55:2413-26.
2. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111-9.
3. Orszulak TA, Schaff HV, Mullany CJ, Anderson BJ, Ilstrup DM, Puga FJ et al. Risk of thromboembolism with the aortic Carpentier-Edwards bioprosthesis. Ann Thorac Surg 1995;59:462-8.
4. ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg 2010;139: 1137-45.
5. Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 2004;110:496-500.
6. Bonow RO, Carabello B, de Leon AC, Edmunds LH Jr, Fedderly BJ, Freed MD et al. ACC/AHA guidelines for the management of patients with valvular heart disease. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Heart Valve Dis 1998;7:672-707.
7. Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005;26:2463-71.
8. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119:220S-7S.
9. Goldsmith I, Turpie AG, Lip GY. Valvar heart disease and prosthetic heart valves. BMJ 2002;325:1228-31.
10. Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/ repair. J Heart Valve Dis 2005;14:576-82.
11. Colli A, Verhoye JP, Heijmen R, Strauch JT, Hyde JA, Pagano D et al. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg 2008;33:531-6.
12. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006;48:e1-48.
13. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008;34:73-92.
14. Babin-Ebell J, Schmidt W, Eigel P, Elert O. Aortic bioprosthesis without early anticoagulation-risk of thromboembolism. Thorac Cardiovasc Surg 1995;43:212-4.
15. Moinuddeen K, Quin J, Shaw R, Dewar M, Tellides G, Kopf G et al. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation 1998;98:II95-8; discussion II98-9.
16. Mistiaen W, Van Cauwelaert P, Muylaert P, Sys SU, Harrisson F, Bortier H. Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg 2004;127:1166-70.
17. Sundt TM, Zehr KJ, Dearani JA, Daly RC, Mullany CJ, McGregor CG et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 2005;129:1024-31.
18. Aramendi JI, Mestres CA, Martinez-Leon J, Campos V, Munoz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005;27:854-60.
19. Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 2007;16:667-71.
20. Jamieson WR, Moffatt-Bruce SD, Skarsgard P, Hadi MA, Ye J, Fradet GJ et al. Early antithrombotic therapy for aortic valve bioprostheses: is there an indication for routine use? Ann Thorac Surg 2007;83:549-56; discussion 556-557.
21. Brueck M, Kramer W, Vogt P, Steinert N, Roth P, Gorlach G et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg 2007;32:108-12.
22. di Marco F, Grendene S, Feltrin G, Meneghetti D, Gerosa G. Antiplatelet therapy in patients receiving aortic bioprostheses: a report of clinical and instrumental safety. J Thorac Cardiovasc Surg 2007;133: 1597-603.
23. Nowell J, Jahangiri M. Anticoagulation after bioprosthetic aortic valve replacement. J Thorac Cardiovasc Surg 2010;140:1201-2; author reply 1202.
24. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
25. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.